Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Owning 47% Shares,institutional Owners Seem Interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $15
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $14
Express News | Monte Rosa Therapeutics Inc : JP Morgan Raises Target Price to $15 From $7